Published in Proc Natl Acad Sci U S A on March 07, 2003
New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol (2003) 2.09
Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog (2009) 1.58
Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A (2007) 1.31
2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem (2011) 1.19
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure. J Mol Biol (2012) 0.99
Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol (2005) 0.97
Chemical induction of misfolded prion protein conformers in cell culture. J Biol Chem (2009) 0.97
Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum. Bioorg Med Chem (2005) 0.95
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology (2013) 0.91
Cyclodextrins inhibit replication of scrapie prion protein in cell culture. J Virol (2007) 0.89
Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro. Antimicrob Agents Chemother (2007) 0.86
A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets. J Biol Chem (2011) 0.86
Potent inhibition of tau fibrillization with a multivalent ligand. Biochem Biophys Res Commun (2007) 0.85
Quinacrine promotes replication and conformational mutation of chronic wasting disease prions. Proc Natl Acad Sci U S A (2014) 0.85
Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int J Cell Biol (2013) 0.82
Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells. Mol Med (2007) 0.82
Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J Virol (2006) 0.82
Acridine derivatives inhibit lysozyme aggregation. Eur Biophys J (2008) 0.80
Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. Bioorg Med Chem (2013) 0.78
Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time. Cell Mol Neurobiol (2008) 0.78
Mechanistic insights into the cure of prion disease by novel antiprion compounds. J Virol (2007) 0.77
Structure-activity relationship of cyclic thiacarbocyanine tau aggregation inhibitors. Bioorg Med Chem Lett (2011) 0.77
The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion. Biomaterials (2011) 0.76
G-quadruplexes within prion mRNA: the missing link in prion disease? Nucleic Acids Res (2014) 0.76
QSAR study of anti-prion activity of 2-aminothiazoles. EXCLI J (2012) 0.75
An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models. Sci Rep (2016) 0.75
Prions. Proc Natl Acad Sci U S A (1998) 27.80
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature (2002) 10.81
Prion protein biology. Cell (1998) 4.20
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res (2002) 3.79
Structural clues to prion replication. Science (1994) 3.43
Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A (1999) 3.43
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A (2001) 3.39
Pathway complexity of prion protein assembly into amyloid. J Biol Chem (2002) 2.96
Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 2.78
Transmission of prion diseases by blood transfusion. J Gen Virol (2002) 2.42
Cultured cell sublines highly susceptible to prion infection. J Virol (2000) 2.38
A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol (1997) 2.32
Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol (2000) 2.15
DNA polyintercalating drugs: DNA binding of diacridine derivatives. Proc Natl Acad Sci U S A (1975) 1.91
Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A (1998) 1.80
Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov (2002) 1.63
Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet (2000) 1.54
Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci U S A (2000) 1.41
Branched polyamines cure prion-infected neuroblastoma cells. J Virol (2001) 1.32
Human prion diseases. Ann Neurol (1994) 1.31
Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker. J Med Chem (2000) 1.20
Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J Gen Virol (2000) 1.01
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. J Med Chem (1985) 0.98
Diacridines, bifunctional intercalators. Chemistry and antitumor activity. J Med Chem (1978) 0.94
Pharmacological approaches to prion research. Biochem Pharmacol (2002) 0.87
Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology (2002) 0.86
Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet (2001) 0.84
9-acridinyl and 2-methoxy-6-chloro-9-acridinyl derivatives of aliphatic di-, tri-, and tetraamines. Chemistry, cytostatic activity, and schistosomicidal activity. J Med Chem (1983) 0.80
Transgenetics and neuropathology of prion diseases. Curr Top Microbiol Immunol (1996) 0.80
[DNA-intercalating compounds. Synthesis of acridine dimers]. C R Acad Sci Hebd Seances Acad Sci D (1975) 0.79
Synthetic mammalian prions. Science (2004) 7.35
Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol (2003) 4.24
Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A (2004) 3.64
A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron (2002) 3.36
GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res (2003) 3.34
Prions. Cold Spring Harb Perspect Biol (2011) 3.17
Automated extraction of mutation data from the literature: application of MuteXt to G protein-coupled receptors and nuclear hormone receptors. Bioinformatics (2004) 3.03
Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol (2008) 2.98
Pathway complexity of prion protein assembly into amyloid. J Biol Chem (2002) 2.96
Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci U S A (2002) 2.91
Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci U S A (2006) 2.69
Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci U S A (2009) 2.41
Silver nanowires as surface plasmon resonators. Phys Rev Lett (2005) 2.38
Analysis of proteome dynamics in the mouse brain. Proc Natl Acad Sci U S A (2010) 2.37
Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A (2012) 2.36
Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A (2007) 2.34
Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci U S A (2005) 2.25
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol (2002) 2.24
Transmission and detection of prions in feces. J Infect Dis (2008) 2.20
Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A (2013) 2.19
Protease-sensitive synthetic prions. PLoS Pathog (2010) 2.14
Diagnosis of human prion disease. Proc Natl Acad Sci U S A (2005) 2.13
Asymptomatic deer excrete infectious prions in faeces. Nature (2009) 2.10
Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des (2006) 2.10
Mutant PrPSc conformers induced by a synthetic peptide and several prion strains. J Virol (2004) 2.07
Transmission of elk and deer prions to transgenic mice. J Virol (2006) 2.03
Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc Natl Acad Sci U S A (2003) 2.01
Natural and synthetic prion structure from X-ray fiber diffraction. Proc Natl Acad Sci U S A (2009) 1.97
Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A (2005) 1.91
Prion clearance in bigenic mice. J Gen Virol (2005) 1.79
Co-evolutionary analysis reveals insights into protein-protein interactions. J Mol Biol (2002) 1.77
Conformational transformation and selection of synthetic prion strains. J Mol Biol (2011) 1.66
Copper coordination in the full-length, recombinant prion protein. Biochemistry (2003) 1.66
Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci U S A (2002) 1.65
Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem (2002) 1.64
Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nat Biotechnol (2004) 1.63
Measuring prions by bioluminescence imaging. Proc Natl Acad Sci U S A (2009) 1.59
Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog (2009) 1.58
Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A (2009) 1.56
Polio and Nobel prizes: looking back 50 years. Ann Neurol (2007) 1.54
Genes contributing to prion pathogenesis. J Gen Virol (2008) 1.51
Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell Biol (2003) 1.51
Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol (2009) 1.51
Prion proteins in subpopulations of white blood cells from patients with sporadic Creutzfeldt-Jakob disease. Lab Invest (2009) 1.48
Prions in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.48
Automatic extraction of protein point mutations using a graph bigram association. PLoS Comput Biol (2007) 1.48
Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J Neurochem (2005) 1.45
Molecular phylogeny and evolution of the plant-specific seven-transmembrane MLO family. J Mol Evol (2003) 1.45
The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest (2012) 1.45
Search for a prion-specific nucleic acid. J Virol (2005) 1.44
Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci U S A (2008) 1.43
Transmission barriers for bovine, ovine, and human prions in transgenic mice. J Virol (2005) 1.43
Inactivation of prions by acidic sodium dodecyl sulfate. J Virol (2006) 1.43
Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A (2011) 1.39
Cytosolic prion protein in neurons. J Neurosci (2003) 1.34
Incorporation of unprotected heterocyclic side chains into peptoid oligomers via solid-phase submonomer synthesis. J Am Chem Soc (2003) 1.34
Do ligand binding and solvent exclusion alter the electrostatic character within the oxyanion hole of an enzymatic active site? J Am Chem Soc (2007) 1.31
A data processing pipeline for mammalian proteome dynamics studies using stable isotope metabolic labeling. Mol Cell Proteomics (2011) 1.31
Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. Biochem Pharmacol (2005) 1.31
Cell division modulates prion accumulation in cultured cells. Proc Natl Acad Sci U S A (2007) 1.25
Locally disordered conformer of the hamster prion protein: a crucial intermediate to PrPSc? Biochemistry (2002) 1.24
Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Mal-dependent inflammatory responses. J Neuroimmunol (2008) 1.24
Prion uptake in the gut: identification of the first uptake and replication sites. PLoS Pathog (2011) 1.21
Evaluation of bacterial nitrate reduction in the human oral cavity. Eur J Oral Sci (2005) 1.21
2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem (2011) 1.19
Notch-1 activation and dendritic atrophy in prion disease. Proc Natl Acad Sci U S A (2005) 1.17
De novo generation of prion strains. Nat Rev Microbiol (2011) 1.17
Transmission of scrapie and sheep-passaged bovine spongiform encephalopathy prions to transgenic mice expressing elk prion protein. J Gen Virol (2009) 1.15
The neurodegeneration sequence in prion diseases: evidence from functional, morphological and ultrastructural studies of the GABAergic system. J Neuropathol Exp Neurol (2004) 1.14
Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation. PLoS Pathog (2008) 1.14
Assembly of natural and recombinant prion protein into fibrils. Biol Chem (2005) 1.13
Cryo-immunogold electron microscopy for prions: toward identification of a conversion site. J Neurosci (2008) 1.12
Drug resistance confounding prion therapeutics. Proc Natl Acad Sci U S A (2013) 1.10
Spontaneous generation of anchorless prions in transgenic mice. Proc Natl Acad Sci U S A (2011) 1.08
Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites. J Mol Biol (2007) 1.07
Human prion strain selection in transgenic mice. Ann Neurol (2010) 1.06
Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol (2006) 1.06
Toward the synthesis of artificial proteins: the discovery of an amphiphilic helical peptoid assembly. Chem Biol (2002) 1.05
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem (2007) 1.05
Bandlike transport in strongly coupled and doped quantum dot solids: a route to high-performance thin-film electronics. Nano Lett (2012) 1.04
Colloid formation by drugs in simulated intestinal fluid. J Med Chem (2010) 1.04
Differences between the prion protein and its homolog Doppel: a partially structured state with implications for scrapie formation. J Mol Biol (2002) 1.04
The peculiar nature of unfolding of the human prion protein. Protein Sci (2004) 1.04
Metal-enhanced upconversion luminescence tunable through metal nanoparticle-nanophosphor separation. ACS Nano (2012) 1.03